2027 ICD-10-CM Diagnosis Code C50.829Malignant neoplasm of overlapping sites of unspecified male breast
ICD-10-CM Codes›C00–D49›C50›C50
- Billable — Valid for Submission
- Risk Adjusts — HCC 23
- Chronic Condition
C50.829 is a billable ICD-10-CM diagnosis code for malignant neoplasm of overlapping sites of unspecified male breast. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 582 through 583, 597 through 599. Coders also document this condition as malignant neoplasm of overlapping sites of breast. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Breast cancer - all other types.
For Medicare Advantage risk adjustment, C50.829 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C50.829 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Malignant neoplasm of overlapping sites of breast
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to C50.829: its own notes plus those printed at C50 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Includes
Further defines, or gives examples of, the content of the category.
- connective tissue of breast
- Paget's disease of breast
- Paget's disease of nipple
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Use Additional Code
Add a second code, after this one, to fully describe the condition.
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name C50.829, its category, or a range that includes it.
Applicable To 2
These notes mention C50.829.
Excludes1 4
These codes carry an Excludes1 note naming C50.829: they are not reported together with it, unless the two conditions are unrelated.
- C49 Malignant neoplasm of other connective and soft tissuemalignant neoplasm of connective tissue of breast (C50.-) names C50.-, which includes this code
- C49.3 Malignant neoplasm of connective and soft tissue of thoraxmalignant neoplasm of breast (C50.-) names C50.-, which includes this code
- D05 Carcinoma in situ of breastmalignant neoplasm of breast (C50.-) names C50.-, which includes this code
- D05 Carcinoma in situ of breastPaget's disease of breast or nipple (C50.-) names C50.-, which includes this code
Code First 3
These codes say to code first a condition named in the note, and C50.829 is one of the conditions named.
- D75.81 Myelofibrosismalignant neoplasm of breast (C50.-) names C50.-, which includes this code
- Z17 Estrogen, and other hormones and factors receptor statusmalignant neoplasm of breast (C50.-) names C50.-, which includes this code
- Z79.81 Long term (current) use of agents affecting estrogen receptors and estrogen levelsmalignant neoplasm of breast (C50.-) names C50.-, which includes this code
Code Also 2
These codes say C50.829 may also be needed to fully describe the condition. The note gives no sequencing direction.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Malignant Breast Neoplasm
a primary or metastatic malignant neoplasm involving the breast. the vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. malignant breast neoplasms occur more frequently in females than in males.
Patient EducationClinical
Male Breast Cancer
Although breast cancer is much more common in women, men can get it too. It happens most often to men between the ages of 60 and 70.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C50.829 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C50.829Overview
What is the ICD-10 code for malignant neoplasm of overlapping sites of unspecified male breast?
The ICD-10-CM code for malignant neoplasm of overlapping sites of unspecified male breast is C50.829 (sometimes written as C50829). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is C50.829 (Malignant neoplasm of overlapping sites of breast, male) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of overlapping sites of unspecified male breast on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does C50.829 group to?
When malignant neoplasm of overlapping sites of unspecified male breast is the principal diagnosis on an inpatient stay, it groups to MS-DRG 598, 582, 599, 597, 583, with relative weights from 0.6756 to 1.8014 depending on complications. Higher weights mean higher Medicare reimbursement.
Can C50.829 be reported with C44.501?
Not as a rule. The Excludes1 note at C50, which applies to C50.829, lists "skin of breast (C44.501, C44.511, C44.521, C44.591)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
Does C50.829 need an additional code?
When the condition applies, yes. The Use Additional Code note at C50, which applies to C50.829, reads: code to identify estrogen, and other hormones and factors receptor status (Z17.-). The additional code is reported after C50.829.
What HCC is C50.829?
C50.829 (malignant neoplasm of overlapping sites of unspecified male breast) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does C50.829 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C50.829 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.
